drugset
drugset / Trial / NCT07432633

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

NCT07432633 ↗

Phase 1/2 Recruiting 71 enrolled Blue Earth Diagnostics Medpace, Inc. · collab
NaSingle-groupOpen-labelDiagnostic

Summary

This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

Timeline

Start
2026-02-19
Primary completion
2028-01-31
Completion
2028-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F]FPyQCP Diagnostic / imaging agent — —

Indications

colorectal cancer gastric cancer invasive lobular breast carcinoma malignant epithelial tumor of ovary pancreatic ductal adenocarcinoma